Montreal, May 9th, 2022
THORASYS is pleased to announce it has successfully closed a round of financing aimed at accelerating its growth and the development of strategic innovation. In this round, 6.3M CAD was led by Desjardins Capital, supported by BDC Capital, the investment arm of the Business Development Bank of Canada, as well as Medteq (pan-Canadian Consortium for Industrial Research and Innovation in Medical Technology) and some private investors. In this transaction, the first tranche of 3.6M CAD is immediately available while the remaining 2.7M CAD may vest within the next 12 months upon the fulfillment of some conditions set by the terms of the agreement.
“This financing comes in timely in the execution of our global growth strategy. We are aiming at speeding up the commercialization of our products in broader geographies while continuing to invest in the diversification of our product portfolio to support patients with respiratory problems. Some of the investors in this round were also part of earlier rounds with THORASYS. To me, this as a testament of trust towards our team who executed on commitments to achieve important milestones in the last years.” - Yvan Beaudoin, CEO of THORASYS.
THORASYS is a health tech company based in Montreal’s Mile-Ex neighbourhood. We develop, manufacture and market state-of-the-art medical technologies that introduce new approaches to the diagnosis and monitoring of lung diseases such as asthma and COPD. Our flagship product, the tremoflo® C-100, has been sold in over 20 countries worldwide over the last decade. THORASYS’ mission is to revolutionize the practice of pulmonary medicine through innovative and accessible solutions that elevate the care experience of patients globally.